The risks of ubiquinone and β-carotene deficiency and metabolic disorders in patients with oral cancer.

Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Metabolic Diseases/*epidemiology ; Mouth Neoplasms/*pathology ; Ubiquinone/*deficiency ; beta Carotene/*deficiency; Adult ; Aged ; C-Reactive Protein/metabolism ; Cross-Sectional Studies ; Female ; Humans ; Interleukin-6/blood ; Male ; Metabolic Diseases/blood ; Metabolic Diseases/classification ; Middle Aged ; Mouth Neoplasms/blood ; Neoplasm Staging ; Oxidative Stress ; Vitamin A/blood ; Vitamin E/blood

Background: Cancer development is mediated by oxidative stress and inflammation, which may correlate with metabolic disorders. The aim of this study was to evaluate antioxidant vitamins status and metabolic parameters in patients with oral cancer according to tumor-node-metastasis (TNM) stages.
Methods: A total of 194 patients with oral cancer were enrolled in this study. The patients were stratified for four groups according to cancer stages and that the statistics are comparisons across these groups. The levels of antioxidant vitamins (ubiquinone, β-carotene, vitamin A and E), metabolic parameters, oxidative stress, antioxidant enzymes activity, and inflammatory markers were measured.
Results: More than half of the subjects had high blood pressure, central obesity, hyperglycemia, and hyperlipidemia regardless of TNM stage. With regard to antioxidant vitamins status, 46 and 94% of patients had β-carotene and ubiquinone deficiency, respectively. Patients in T3 and T4 stages had significantly lower antioxidant enzyme (catalase, p = 0.03) activity and higher inflammatory markers levels (high sensitivity C-reactive protein and interleukin-6, p < 0.01) than patients in the other stages. In addition, the level of β-carotene was negatively associated with waist circumference, and ubiquinone was positively associated with the level of high-density lipoprotein cholesterol (p < 0.05). Higher β-carotene and ubiquinone levels were negatively associated with hypertriglyceridemia and the risk of metabolic syndrome (p < 0.05).
Conclusions: A high proportion of patients with oral cancer had ubiquinone or β-carotene deficiency and metabolic disorders. The level of ubiquinone or β-carotene was negatively associated with the risk of central obesity, hypertriglyceridemia, and metabolic syndrome. Since patients with oral cancer suffer from high oxidative stress and inflammation (particularly in the T3 and T4 stages), supplementation with antioxidant vitamins such as ubiquinone or β-carotene could be preferentially applied.

BMJ Open. 2015 Dec 18;5(12):e008788. (PMID: 26685025)
Nutr J. 2016 Oct 6;15(1):85. (PMID: 27716246)
Lancet. 2005 Sep 24-30;366(9491):1059-62. (PMID: 16182882)
J Am Coll Nutr. 2001 Dec;20(6):591-8. (PMID: 11771674)
Prz Menopauzalny. 2014 May;13(2):136-44. (PMID: 26327844)
J Clin Diagn Res. 2014 Apr;8(4):ZC01-3. (PMID: 24959505)
JAMA. 2001 May 16;285(19):2486-97. (PMID: 11368702)
Oncology. 2011;80(5-6):382-9. (PMID: 21829039)
Arch Biochem Biophys. 1998 Apr 15;352(2):229-36. (PMID: 9587410)
Biomed Res Int. 2013;2013:825065. (PMID: 23509785)
Oral Oncol. 2014 Jan;50(1):10-8. (PMID: 24126222)
Clin Biochem Rev. 2008 May;29(2):71-82. (PMID: 18787645)
J Lab Clin Med. 1967 Jul;70(1):158-69. (PMID: 6066618)
Biochem Biophys Res Commun. 1997 May 19;234(2):296-9. (PMID: 9177262)
Free Radic Biol Med. 2012 May 1;52(9):2013-37. (PMID: 22391222)
Arch Otolaryngol Head Neck Surg. 1995 Feb;121(2):141-4. (PMID: 7840919)
Oxid Med Cell Longev. 2016;2016:6859523. (PMID: 26649144)
J Nutr. 2011 May;141(5):903-13. (PMID: 21451127)
J Pharm Biomed Anal. 2006 Sep 18;42(2):232-6. (PMID: 16765550)
Adv Clin Exp Med. 2017 Jul;26(4):581-586. (PMID: 28691410)
Adv Clin Exp Med. 2016 Jul-Aug;25(4):689-700. (PMID: 27629843)
Cancer Res. 1993 Feb 15;53(4):795-8. (PMID: 8428360)
Asian Pac J Cancer Prev. 2014;15(19):8183-9. (PMID: 25339003)
J Cancer Res Ther. 2016 Apr-Jun;12(2):438-46. (PMID: 27461591)
Br J Nutr. 2018 Jul;120(1):57-63. (PMID: 29936921)
PLoS One. 2012;7(9):e45693. (PMID: 23029185)
Free Radic Biol Med. 2010 Dec 1;49(11):1603-16. (PMID: 20840865)
Eur J Cancer Prev. 2003 Aug;12(4):321-6. (PMID: 12883386)
Arch Biochem Biophys. 1995 Nov 10;323(2):343-51. (PMID: 7487097)
Eur J Biochem. 1974 Sep 16;47(3):469-74. (PMID: 4215654)
Exp Biol Med (Maywood). 2016 Jun;241(12):1281-95. (PMID: 27022139)
ScientificWorldJournal. 2013 Sep 03;2013:767968. (PMID: 24082857)
Nutrients. 2017 Jan 04;9(1):. (PMID: 28054958)
Circulation. 2005 Oct 25;112(17):2735-52. (PMID: 16157765)
Oxid Med Cell Longev. 2018 May 21;2018:9303094. (PMID: 29951168)
Br J Cancer. 1988 Apr;57(4):428-33. (PMID: 3390380)
Niger J Clin Pract. 2012 Jan-Mar;15(1):30-3. (PMID: 22437085)
Methods Enzymol. 1984;105:121-6. (PMID: 6727660)
Oral Dis. 2010 Jan;16(1):29-33. (PMID: 19656315)
Asia Pac J Clin Nutr. 2013;22(1):60-8. (PMID: 23353612)
Head Neck. 2006 Nov;28(11):998-1007. (PMID: 16906513)

MOHW103-TD-B-111-10, MOHW104-TDU-B-211-124004, MOHW105-TDU-B-211-134002 and MOHW106-TDU-B-211-144002 Ministry of Health and Welfare; TCVGH-1085606C Taichung Veterans General Hospital

Keywords: Antioxidant vitamins; Metabolic disorders; Oral cancer; Ubiquinone; β-Carotene

0 (IL6 protein, human)
0 (Interleukin-6)
01YAE03M7J (beta Carotene)
11103-57-4 (Vitamin A)
1339-63-5 (Ubiquinone)
1406-18-4 (Vitamin E)
9007-41-4 (C-Reactive Protein)

Date Created: 20200416 Date Completed: 20201218 Latest Revision: 20201218

20240829

PMC7161249

10.1186/s12885-020-06839-9

32293339